IL-WEBER
Weber LLC, the global leader in outdoor cooking innovation, technology, and products, announced today its LUMIN electric grill received a Red Dot Award in the Red Dot Award: Product Design 2024 competition. The Red Dot Design Award, established in 1955, is one of the world’s largest and most prestigious design competitions, receiving more than 20,000 annual submissions from approximately 60 countries worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240516349562/en/
The Weber LUMIN electric grill received a Red Dot Award in the Red Dot Award: Product Design 2024 competition. (Photo: Business Wire)
The Weber LUMIN electric grill, featuring a sleek, space-efficient, contemporary silhouette, received the Red Dot Award for its innovative and high-quality design. It is an ideal grill for outdoor cooks with limited space who desire eco-conscious fuel choices, or who live in a location where other forms of grilling are not permitted.
ABOUT THE LUMIN ELECTRIC GRILL
The LUMIN electric grill, introduced in 2023, is a highly versatile, multifunctional product. Its ultra-modern, space-efficient design makes it ideal for smaller outdoor areas such as balconies and terraces.
To create a “next-level” electric cooking experience, Weber product experts engineered this first-of-its-kind grill to:
- Reach high heat temperatures of more than 600°F/315°C so that cooks can achieve that mouthwatering, authentically grilled flavor they have come to love with Weber products; owners can reach high heat-searing temperatures within 15 minutes.
- Infuse vegetables and proteins with rich, smokey tastes through a unique smoke mode.
- Steam vegetables, braise sausages, and keep cooked food warm via different cook settings and specially designed accessories.
- Thaw frozen foods directly on the grill while it preheats to save time and simplify mealtime.
- Make clean-up easy with a front-access grease tray and dishwasher-friendly, porcelain-enamel cast iron cooking grates.
The LUMIN electric grill also features a porcelain-enamel steel lid and cookbox for superior durability and long-term corrosion resistance.
The LUMIN electric grill is available for purchase on weber.com and from retail partners across the Americas and Europe. Outdoor cooks can select from full-size or compact models and a variety of vibrant colors, including Ice Blue, Deep Ocean Blue, Golden Yellow, Seafoam Green, Crimson, and timeless Black. Available models and colors vary by geographic region.
ABOUT RED DOT DESIGN AWARDS
Every year, the renowned Red Dot Award: Product Design honors products that impress with their exceptionally high design quality. The award is based on the decision of the Red Dot jury, which consists of 39 experts from 20 countries on four continents. The experts assess the submissions based on the four basic principles of good design: the quality of function, the quality of seduction, the quality of use and the quality of responsibility.
ABOUT WEBER LLC
Weber LLC, headquartered in Palatine, Ill., is the world’s leading barbecue brand. The Company’s founder George Stephen, Sr., established the outdoor cooking category when he invented the original kettle charcoal grill more than 70 years ago. Weber offers a comprehensive, innovative product portfolio, including charcoal, gas, pellet, electric grills, smokers, griddles and accessories, designed to bring people together to create amazing memories and delicious food. Weber offers its products, services and experiences to a passionate community of millions across 78 countries.
WEBER and LUMIN are registered U.S. and EU trademarks owned by Weber-Stephen Products LLC. WEBER and LUMIN are also the subject of registrations or pending applications in other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240516349562/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom